|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Bristol_Myers_Squibb
|
|
gptkbp:acquisitionYear
|
2019
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:focusArea
|
gptkb:cancer
immunology
inflammatory disorders
|
|
gptkbp:founded
|
1986
|
|
gptkbp:foundedBy
|
gptkb:Robert_J._Hugin
gptkb:Sol_J._Barer
gptkb:David_Stirling
gptkb:John_W._Jackson
|
|
gptkbp:headquartersLocation
|
gptkb:Summit,_New_Jersey,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Celgene
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Mark_J._Alles
gptkb:Robert_J._Hugin
|
|
gptkbp:location
|
gptkb:New_Jersey
gptkb:mountain
|
|
gptkbp:netIncome
|
$4.0 billion (2018)
|
|
gptkbp:notableEvent
|
acquisition by Bristol Myers Squibb for $74 billion
|
|
gptkbp:notableInvention
|
gptkb:pomolidomide
gptkb:thalidomide
gptkb:lenalidomide
|
|
gptkbp:numberOfEmployees
|
~8,000 (2018)
|
|
gptkbp:parentCompany
|
gptkb:Bristol_Myers_Squibb
|
|
gptkbp:product
|
gptkb:Pomalyst
gptkb:Revlimid
gptkb:Vidaza
gptkb:Abraxane
|
|
gptkbp:researchInterest
|
immunology
oncology
hematology
|
|
gptkbp:revenue
|
$13.0 billion (2018)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:status
|
defunct (as of 2019)
|
|
gptkbp:stockSymbol
|
gptkb:CELG
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:type
|
public (before acquisition)
|
|
gptkbp:website
|
www.celgene.com
|
|
gptkbp:bfsParent
|
gptkb:Array_BioPharma
gptkb:Juno_Therapeutics
|
|
gptkbp:bfsLayer
|
5
|